FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097924418> ?p ?o ?g. }

• W2097924418 endingPage "828" @default.
• W2097924418 startingPage "819" @default.
• W2097924418 abstract "Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the standard of care for advanced biliary cancers. We investigated the addition of cetuximab to chemotherapy in patients with advanced biliary cancers.In this non-comparative, open-label, randomised phase 2 trial, we recruited patients with locally advanced (non-resectable) or metastatic cholangiocarcinoma, gallbladder carcinoma, or ampullary carcinoma and a WHO performance status of 0 or 1 from 18 hospitals across France and Germany. Eligible patients were randomly assigned (1:1) centrally with a minimisation procedure to first-line treatment with gemcitabine (1000 mg/m(2)) and oxaliplatin (100 mg/m(2)) with or without cetuximab (500 mg/m(2)), repeated every 2 weeks until disease progression or unacceptable toxicity. Randomisation was stratified by centre, primary site of disease, disease stage, and previous treatment with curative intent or adjuvant therapy. Investigators who assessed treatment response were not masked to group assignment. The primary endpoint was the proportion of patients who were progression-free at 4 months, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00552149.Between Oct 10, 2007, and Dec 18, 2009, 76 patients were assigned to chemotherapy plus cetuximab and 74 to chemotherapy alone. 48 (63%; 95% CI 52-74) patients assigned to chemotherapy plus cetuximab and 40 (54%; 43-65) assigned to chemotherapy alone were progression-free at 4 months. Median progression-free survival was 6·1 months (95% CI 5·1-7·6) in the chemotherapy plus cetuximab group and 5·5 months (3·7-6·6) in the chemotherapy alone group. Median overall survival was 11·0 months (9·1-13·7) in the chemotherapy plus cetuximab group and 12·4 months (8·6-16·0) in the chemotherapy alone group. The most common grade 3-4 adverse events were peripheral neuropathy (in 18 [24%] of 76 patients who received chemotherapy plus cetuximab vs ten [15%] of 68 who received chemotherapy alone), neutropenia (17 [22%] vs 11 [16%]), and increased aminotransferase concentrations (17 [22%] vs ten [15%]). 70 serious adverse events were reported in 39 (51%) of 76 patients who received chemotherapy plus cetuximab (34 events in 19 [25%] patients were treatment-related), whereas 41 serious adverse events were reported in 25 (35%) of 71 patients who received chemotherapy alone (20 events in 12 [17%] patients were treatment-related). One patient died of atypical pneumonia related to treatment in the chemotherapy alone group.The addition of cetuximab to gemcitabine and oxaliplatin did not seem to enhance the activity of chemotherapy in patients with advanced biliary cancer, although it was well tolerated. Gemcitabine and platinum-based combination should remain the standard treatment option.Institut National du Cancer, Merck Serono." @default.
• W2097924418 created "2016-06-24" @default.
• W2097924418 creator A5002864173 @default.
• W2097924418 creator A5003678097 @default.
• W2097924418 creator A5007810585 @default.
• W2097924418 creator A5017132355 @default.
• W2097924418 creator A5019536561 @default.
• W2097924418 creator A5020704795 @default.
• W2097924418 creator A5020985866 @default.
• W2097924418 creator A5021152840 @default.
• W2097924418 creator A5023596460 @default.
• W2097924418 creator A5028938155 @default.
• W2097924418 creator A5039119608 @default.
• W2097924418 creator A5039743409 @default.
• W2097924418 creator A5041662580 @default.
• W2097924418 creator A5043053032 @default.
• W2097924418 creator A5043245662 @default.
• W2097924418 creator A5044943441 @default.
• W2097924418 creator A5046820642 @default.
• W2097924418 creator A5049515095 @default.
• W2097924418 creator A5051076722 @default.
• W2097924418 creator A5057000867 @default.
• W2097924418 creator A5060536774 @default.
• W2097924418 creator A5060691425 @default.
• W2097924418 creator A5082631947 @default.
• W2097924418 creator A5083715777 @default.
• W2097924418 creator A5085121407 @default.
• W2097924418 date "2014-07-01" @default.
• W2097924418 modified "2023-10-18" @default.
• W2097924418 title "Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial" @default.
• W2097924418 cites W1981051246 @default.
• W2097924418 cites W1988442083 @default.
• W2097924418 cites W1996167718 @default.
• W2097924418 cites W2000366267 @default.
• W2097924418 cites W2020014734 @default.
• W2097924418 cites W2025769688 @default.
• W2097924418 cites W2029409133 @default.
• W2097924418 cites W2042048917 @default.
• W2097924418 cites W2065756402 @default.
• W2097924418 cites W2067486928 @default.
• W2097924418 cites W2078691662 @default.
• W2097924418 cites W2087336559 @default.
• W2097924418 cites W2094501197 @default.
• W2097924418 cites W2114327118 @default.
• W2097924418 cites W2115261608 @default.
• W2097924418 cites W2117834374 @default.
• W2097924418 cites W2118520585 @default.
• W2097924418 cites W2135849593 @default.
• W2097924418 cites W2138604360 @default.
• W2097924418 cites W2139248078 @default.
• W2097924418 cites W2141750100 @default.
• W2097924418 cites W2154711900 @default.
• W2097924418 cites W2156359059 @default.
• W2097924418 cites W2166400927 @default.
• W2097924418 cites W2168106806 @default.
• W2097924418 cites W2238587635 @default.
• W2097924418 cites W2332605220 @default.
• W2097924418 cites W937179485 @default.
• W2097924418 doi "https://doi.org/10.1016/s1470-2045(14)70212-8" @default.
• W2097924418 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6372099" @default.
• W2097924418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24852116" @default.
• W2097924418 hasPublicationYear "2014" @default.
• W2097924418 type Work @default.
• W2097924418 sameAs 2097924418 @default.
• W2097924418 citedByCount "328" @default.
• W2097924418 countsByYear W20979244182014 @default.
• W2097924418 countsByYear W20979244182015 @default.
• W2097924418 countsByYear W20979244182016 @default.
• W2097924418 countsByYear W20979244182017 @default.
• W2097924418 countsByYear W20979244182018 @default.
• W2097924418 countsByYear W20979244182019 @default.
• W2097924418 countsByYear W20979244182020 @default.
• W2097924418 countsByYear W20979244182021 @default.
• W2097924418 countsByYear W20979244182022 @default.
• W2097924418 countsByYear W20979244182023 @default.
• W2097924418 crossrefType "journal-article" @default.
• W2097924418 hasAuthorship W2097924418A5002864173 @default.
• W2097924418 hasAuthorship W2097924418A5003678097 @default.
• W2097924418 hasAuthorship W2097924418A5007810585 @default.
• W2097924418 hasAuthorship W2097924418A5017132355 @default.
• W2097924418 hasAuthorship W2097924418A5019536561 @default.
• W2097924418 hasAuthorship W2097924418A5020704795 @default.
• W2097924418 hasAuthorship W2097924418A5020985866 @default.
• W2097924418 hasAuthorship W2097924418A5021152840 @default.
• W2097924418 hasAuthorship W2097924418A5023596460 @default.
• W2097924418 hasAuthorship W2097924418A5028938155 @default.
• W2097924418 hasAuthorship W2097924418A5039119608 @default.
• W2097924418 hasAuthorship W2097924418A5039743409 @default.
• W2097924418 hasAuthorship W2097924418A5041662580 @default.
• W2097924418 hasAuthorship W2097924418A5043053032 @default.
• W2097924418 hasAuthorship W2097924418A5043245662 @default.
• W2097924418 hasAuthorship W2097924418A5044943441 @default.
• W2097924418 hasAuthorship W2097924418A5046820642 @default.
• W2097924418 hasAuthorship W2097924418A5049515095 @default.
• W2097924418 hasAuthorship W2097924418A5051076722 @default.
• W2097924418 hasAuthorship W2097924418A5057000867 @default.
• W2097924418 hasAuthorship W2097924418A5060536774 @default.
• W2097924418 hasAuthorship W2097924418A5060691425 @default.

• next